Monoclonal Antibodies for Prurigo Nodularis: Current Landscape and Future Directions

Prurigo nodularis (PN) is a chronic skin condition that develops intensely itchy nodules, substantially reducing patients’ quality of life. Immune system irregularities, neuroinflammation, and constant scratching damage the skin barrier to produce this condition. Corticosteroids and antihistamines, as traditional treatments, corticosteroids and antihistamines frequently fail to provide sufficient relief from symptoms, requiring specific biologic therapies. The latest progress in the field has led to the development of monoclonal antibodies that focus on essential pruritogenic pathways.